Reports
Sale
Global Bronchodilators Market Size, Share, Report, Forecast: By Type: Beta-Adrenergic Bronchodilators, Xanthine Derivatives, Anticholinergic Bronchodilators, Others; By Indication: Asthma, Chronic Obstructive Pulmonary Disease (COPD), Others; By Route of Administration; By End User; Regional Analysis; Supplier Landscape; 2024-2032
Global Bronchodilators Market Outlook
The bronchodilators market size was valued at USD 29.3 billion in 2023, driven by the rising incidence of chronic lung diseases like COPD and asthma across the globe. The market is expected to grow at a CAGR of 4.6% during the forecast period of 2024-2032, with the values likely to rise from USD 30.6 billion in 2024 to USD 43.9 billion by 2032.
Bronchodilators: Introduction
A bronchodilator is a medication that helps in the relaxation of the muscles around the bronchi, facilitating easy breathing. It is usually used to relieve the symptoms of asthma, COPD (chronic obstructive pulmonary disease) and other lung diseases. A bronchodilator helps clean the mucus from lungs, allowing it to move freely and get out of the body easily.
There are two forms, mainly short-acting bronchodilators that are effective for 3-6 hours while long-acting bronchodilators that provide help up to 12 hours. They are available as inhalers and nebulizers.
Bronchodilators Market Analysis
With the emergence of COVID-19, the bodies have become more susceptible to chronic respiratory illnesses. β2 adrenoceptor agonists bronchodilators have also found their application as an alternative treatment for treating COVID infected patients, as a result, bronchodilators market demand has seen an upswing in the historic period.
The incidence of chronic lung diseases has led to an increased demand for quality treatment for patients. Bronchodilators are still widely used to treat both COPD and asthma, hence, there have been several new advancements in the existing technology. A contemporary approach to formulate a new dual bronchodilator therapy is in the works. This drug class called MABA has both mAChR antagonism and β2-agonist activity in one molecule. It is believed to be better than the existing combinations due to its ‘triple therapy’ (treatment alternative for COPD) feature. The MABA Batefenterol is under an advanced clinical development stage.
Bronchodilator drugs are also used in combinations to treat lung diseases. For instance, AstraZenenca got the first and only asthma exacerbation risk reducing medication Airsupra (PT027) approved by the FDA in January 2023.It is the first ever drug that contains a combination of albuterol (β2 adrenergic agonist) and budesonide (corticosteroid). With increased application and demand, it is a clear indicator that bronchodilator market growth is certain in the upcoming years.
Bronchodilators Market Segmentation
Market Breakup by Drug Class
- Beta-Adrenergic Bronchodilators
- Xanthine Derivatives
- Anticholinergic Bronchodilators
- Others
Market Breakup by Indication
- Asthma
- Chronic Obstructive Pulmonary Disease (COPD)
- Allergic Reactions
- Breathing Problem
- Others
Market Breakup by Route of Administration
- Oral
- Parenteral
- Inhalational
- Others
Market Breakup by End User
- Hospitals
- Speciality Clinics
- Home Healthcare
- Others
Market Breakup by Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Bronchodilators Market Overview
It is estimated that over 300 million asthma patients carry the burden of high morbidities and mortalities across the world. As a result, the bronchodilator market value has risen, with the vision to mitigate the number of morbidities associated with chronic respiratory diseases. The Asia Pacific region is expected to experience rapid growth in terms of market share owing to the presence of a geriatric population in the region. As a precautionary measure, the governments are more alert and working regularly by setting up several awareness campaigns.
The United States is anticipated to lead the bronchodilator market share, which is influenced by the existence of several healthcare leaders in the area. United States healthcare industry is always thriving to bring new innovations in the market. For instance, in a recent trial, Sanofi's Dupixent® showcased significant clinical potential to reduce COPD aggravations by 30%. This indicates that the country is set to experience the latest technological advances exclusively.
Bronchodilators Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Bayer AG
- Teva Pharmaceutical Industries Ltd.
- Sun Pharmaceutical Industries Ltd.
- Hikma Pharmaceutical PLC
- Amneal Pharmaceuticals LLC
- Aurobindo Pharma
- Johnsons & Johnsons Services Pvt Ltd
- GSK Plc
- Thermo Fisher Scientific Inc.
- Siemens
- Cipla Inc.
- AstraZeneca
- Mylan N.V.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Type |
|
| Breakup by Indication |
|
| Breakup by Route of Administration |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Bronchodilators Market Overview
3.1 Global Bronchodilators Market Historical Value (2017-2023)
3.2 Global Bronchodilators Market Forecast Value (2024-2032)
4 Global Bronchodilators Market Landscape
4.1 Global Bronchodilators Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Bronchodilators Product Landscape
4.2.1 Analysis by Drug Class
4.2.2 Analysis by Indication
4.2.3 Analysis by Route of Administration
5 Global Bronchodilators Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter’s Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Bronchodilators Market Segmentation
6.1 Global Bronchodilators Market by Type
6.1.1 Market Overview
6.1.2 Beta-Adrenergic Bronchodilators
6.1.3 Xanthine Derivatives
6.1.4 Anticholinergic Bronchodilators
6.1.5 Others
6.2 Global Bronchodilators Market by Indication
6.2.1 Market Overview
6.2.2 Asthma
6.2.3 Chronic Obstructive Pulmonary Disease (COPD)
6.2.4 Allergic Reactions
6.2.5 Breathing Problem
6.2.6 Others
6.3 Global Bronchodilators Market by Route of Administration
6.3.1 Market Overview
6.3.2 Oral
6.3.3 Parenteral
6.3.4 Inhalational
6.3.5 Others
6.4 Global Bronchodilators Market by End User
6.4.1 Market Overview
6.4.2 Hospitals
6.4.3 Speciality Clinics
6.4.4 Home Healthcare
6.4.5 Others
6.5 Global Bronchodilators Market by Region
6.5.1 Market Overview
6.5.2 North America
6.5.3 Europe
6.5.4 Asia Pacific
6.5.5 Latin America
6.5.6 Middle East and Africa
7 North America Bronchodilators Market
7.1 Market Share by Country
7.2 United States of America
7.3 Canada
8 Europe Bronchodilators Market
8.1 Market Share by Country
8.2 United Kingdom
8.3 Germany
8.4 France
8.5 Italy
8.6 Others
9 Asia Pacific Bronchodilators Market
9.1 Market Share by Country
9.2 China
9.3 Japan
9.4 India
9.5 ASEAN
9.6 Australia
9.7 Others
10 Latin America Bronchodilators Market
10.1 Market Share by Country
10.2 Brazil
10.3 Argentina
10.4 Mexico
10.5 Others
11 Middle East and Africa Bronchodilators Market
11.1 Market Share by Country
11.2 Saudi Arabia
11.3 United Arab Emirates
11.4 Nigeria
11.5 South Africa
11.6 Others
12 Patent Analysis
12.1 Analysis by Type of Patent
12.2 Analysis by Publication year
12.3 Analysis by Issuing Authority
12.4 Analysis by Patent Age
12.5 Analysis by CPC Analysis
12.6 Analysis by Patent Valuation
12.7 Analysis by Key Players
13 Grants Analysis
13.1 Analysis by year
13.2 Analysis by Amount Awarded
13.3 Analysis by Issuing Authority
13.4 Analysis by Grant Application
13.5 Analysis by Funding Institute
13.6 Analysis by NIH Departments
13.7 Analysis by Recipient Organization
14 Clinical Trials Analysis
14.1 Analysis by Trial Registration Year
14.2 Analysis by Trial Status
14.3 Analysis by Trial Phase
14.4 Analysis by Therapeutic Area
14.5 Analysis by Geography
15 Funding & Investment Analysis
15.1 Analysis by Funding Instances
15.2 Analysis by Type of Funding
15.3 Analysis by Funding Amount
15.4 Analysis by Leading Players
15.5 Analysis by Leading Investors
15.6 Analysis by Geography
16 Partnership and Collaborations Analysis
16.1 Analysis by Partnership Instances
16.2 Analysis by Type of Partnership
16.3 Analysis by Leading Players
16.4 Analysis by Geography
17 Regulatory Framework
17.1 Regulatory Overview
17.1.1 US FDA
17.1.2 EU EMA
17.1.3 INDIA CDSCO
17.1.4 JAPAN PMDA
17.1.5 Others
18 Supplier Landscape
18.1 Bayer AG
18.1.1 Financial Analysis
18.1.2 Product Portfolio
18.1.3 Demographic Reach and Achievements
18.1.4 Mergers and Acquisitions
18.1.5 Certifications
18.2 Teva Pharmaceutical Industries Ltd.
18.2.1 Financial Analysis
18.2.2 Product Portfolio
18.2.3 Demographic Reach and Achievements
18.2.4 Mergers and Acquisitions
18.2.5 Certifications
18.3 Sun Pharmaceutical Industries Ltd.
18.3.1 Financial Analysis
18.3.2 Product Portfolio
18.3.3 Demographic Reach and Achievements
18.3.4 Mergers and Acquisitions
18.3.5 Certifications
18.4 Hikma Pharmaceutical PLC
18.4.1 Financial Analysis
18.4.2 Financial Portfolio
18.4.3 Demographic Reach and Achievements
18.4.4 Mergers and Acquisitions
18.4.5 Certifications
18.5 Amneal Pharmaceuticals LLC
18.5.1 Financial Analysis
18.5.2 Product Portfolio
18.5.3 Demographic Reach and Achievements
18.5.4 Mergers and Acquisitions
18.5.5 Certifications
18.6 Aurobindo Pharma
18.6.1 Financial Analysis
18.6.2 Product Portfolio
18.6.3 Demographic Reach and Achievements
18.6.4 Mergers and Acquisitions
18.6.5 Certifications
18.7 Johnsons & Johnsons Services Pvt Ltd
18.7.1 Financial Analysis
18.7.2 Product Portfolio
18.7.3 Demographic Reach and Achievements
18.7.4 Mergers and Acquisitions
18.7.5 Certifications
18.8 GSK Plc
18.8.1 Financial Analysis
18.8.2 Product Portfolio
18.8.3 Demographic Reach and Achievements
18.8.4 Mergers and Acquisitions
18.8.5 Certifications
18.9 Thermo Fisher Scientific Inc.
18.9.1 Financial Analysis
18.9.2 Product Portfolio
18.9.3 Demographic Reach and Achievements
18.9.4 Mergers and Acquisitions
18.9.5 Certifications
18.10 Siemens
18.10.1 Financial Analysis
18.10.2 Product Portfolio
18.10.3 Demographic Reach and Achievements
18.10.4 Mergers and Acquisitions
18.10.5 Certifications
18.11 Cipla Inc.
18.11.1 Financial Analysis
18.11.2 Product Portfolio
18.11.3 Demographic Reach and Achievements
18.11.4 Mergers and Acquisitions
18.11.5 Certifications
18.12 AstraZeneca
18.12.1 Financial Analysis
18.12.2 Product Portfolio
18.12.3 Demographic Reach and Achievements
18.12.4 Mergers and Acquisitions
18.12.5 Certifications
18.13 Mylan N.V.
18.13.1 Financial Analysis
18.13.2 Product Portfolio
18.13.3 Demographic Reach and Achievements
18.13.4 Mergers and Acquisitions
18.13.5 Certifications
19 Global Bronchodilators Market - Distribution Model (Additional Insight)
19.1 Overview
19.2 Potential Distributors
19.3 Key Parameters for Distribution Partner Assessment
20 Key Opinion Leaders (KOL) Insights (Additional Insight)
21 Company Competitiveness Analysis (Additional Insight)
21.1 Very Small Companies
21.2 Small Companies
21.3 Mid-Sized Companies
21.4 Large Companies
21.5 Very Large Companies
22 Payment Methods (Additional Insight)
22.1 Government Funded
22.2 Private Insurance
22.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
The market attained a value of about USD 29.3 billion in 2023, driven by the prevalence of chronic respiratory diseases like asthma and COPD across the globe.
The market is anticipated to grow at a CAGR of 4.6% during the forecast period of 2024-2032, likely to reach a market value of USD 43.9 by 2032.
After the sudden outbreak of COVID-19, bronchodilators are widely used to treat COVID-19 infected people as well. Hence, the market demand has increased.
Several new technology MABA bronchodilators, like Batefenterol, are under advanced clinical trials. They are used being in combination drug treatments for asthma as well. AstraZenenca’s Airsupra (PT027) got the FDA approval in January 2023.
The major regions of the market include North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. North America is currently leading the global market.
The indications include asthma, chronic obstructive pulmonary disease (COPD), allergic reactions, and breathing problem, among others.
Bronchodilators by drug class include beta-adrenergic bronchodilators, xanthine derivatives, and anticholinergic bronchodilators, among others.
The route of administration can be oral, parenteral, and inhalational, among others.
The end users in the market are hospitals, specialty clinics, and home healthcare, among others.
Key players involved in the market are Bayer AG, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Hikma Pharmaceutical PLC, Amneal Pharmaceuticals LLC, Aurobindo Pharma, Johnsons & Johnsons Services Pvt Ltd, GSK Plc, Thermo Fisher Scientific Inc., Siemens, Cipla Inc., Mylan N.V., and AstraZeneca.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 2969
$2699
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 5499
$4999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 6599
$5999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 7699
$6999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER